Lynparza (olaparib)

pCPA File Number: 21464

Negotiation Status:

Concluded with an LOI

Indication(s):

Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CADTH Project Number:

PC0223-000

pCPA Engagement Letter Issued:

2021-07-07

Negotiation Process Concluded:

2022-01-17